FDMT — 4D Molecular Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1650648 ·
Last close
$10.79
Market Cap
$608.33M
52W High
$16.93
52W Low
$6.96
ADV30
949,850
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 4,145,000 | — | -81,218,000 | -78,056,000 | 428,749,000 | 39,104,000 | 90,806,000 |
| Jun 2026 | 3,781,000 | — | -77,025,000 | -72,936,000 | 492,615,000 | 70,372,000 | 84,956,000 |
| Mar 2026 | 3,047,000 | — | -73,620,000 | -68,760,000 | 512,905,000 | 72,488,000 | 61,069,000 |
| Dec 2025 | 85,090,000 | — | 14,715,000 | 19,397,000 | 566,711,000 | 60,241,000 | 61,047,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-156,071,000
Investing CF
$-16,637,000
Financing CF
$165,921,000
CapEx
$-697,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.04
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-858,000,000
Inventory
—
Receivables
$4,611,000
ST Investments
$290,962,000
EBIT TTM
$-197,115,000
Pretax Income TTM
$-179,175,000
Interest Exp TTM
—
Analysts
11
Yahoo Snapshot (yfinance, live)
Total Revenue
$96,064,000
EBITDA
$-208,967,008
Free Cash Flow
$-93,785,872
Enterprise Value
$420,944,096
Total Cash
$306,988,992
Total Debt
$38,413,000
Shares Out
56,379,402
Trailing EPS
$-2.70
Book Value
$6.00
ROE
-56.7%
ROA
-31.4%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 85,209,000 | -159,547,000 | -140,109,000 | 566,711,000 | 61,047,000 | 505,664,000 | -109,082,000 |
| Dec 2024 | 37,000 | -187,841,000 | -160,868,000 | 560,384,000 | 49,778,000 | 510,606,000 | -134,585,000 |
| Dec 2023 | 20,723,000 | -112,867,000 | -100,837,000 | 339,891,000 | 32,062,000 | 307,829,000 | -75,792,000 |
| Dec 2022 | 3,129,000 | -110,032,000 | -107,494,000 | 261,846,000 | 30,509,000 | 231,337,000 | -86,685,000 |
TTM Snapshot
Revenues TTM
$92,008,000
NetIncome TTM
$-179,175,000
OpCashFlow TTM
—
Assets (Latest)
$492,615,000
Forward EPS
$-4.11
Max Pain — expiry 2027-01-15
max pain strike: $12.00 · spot: $10.46 · call oi: 1,512 · put oi: 2,034
Expected Move to 2027-01-15:
±$3.52
(33.70%) —
implied range
$6.94 –
$13.99
· ATM straddle on $10.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CGEM | Cullinan Therapeutics, Inc. | $602.14M | $9.27 | — |
| DBVT | DBV Technologies S.A. | $627.78M | $9.99 | — |
| SRZN | Surrozen, Inc./DE | $571.47M | $29.98 | — |
| SANA | Sana Biotechnology, Inc. | $563.31M | $1.88 | — |
| IAM | Iambic Therapeutics, Inc. | $674.04M | $14.22 | — |
News headlines (Yahoo Finance, 1h cache)
4D Molecular Therapeutics May Benefit From Upcoming Wet AMD Gene Therapy Data, RBC Says
2026-11-16 16:30 · Yahoo
4DMT Announces New Employment Inducement Grants
2026-11-13 21:05 · Yahoo
4D Molecular Therapeutics, Inc. (FDMT) Reports Q3 Loss, Tops Revenue Estimates
2026-11-12 22:05 · Yahoo
4DMT Reports Third Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones
2026-11-12 21:05 · Yahoo
4DMT to Participate in Upcoming Investor Conferences
2026-11-03 13:00 · Yahoo
4D Molecular Therapeutics, Inc. (FDMT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
2026-11-02 14:00 · Yahoo
4D Molecular Therapeutics Targets Wet AMD Injection Burden With 4D-150 Gene Therapy
2026-10-22 11:02 · Yahoo
Cystic Fibrosis Market Poised for Growth During the Forecast Period (2026-2036) as CFTR Modulators Transform Treatment Landscape | DelveInsight
2026-10-21 14:31 · Yahoo
This is the top biotech stock pick from B Riley Securities
2026-09-29 21:24 · Yahoo
OCUL Stock Suffers Sharpest Drop Since February As KOD And FDMT Post Updates On Their Wet AMD Drugs
2026-09-28 17:15 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.